Orchestra BioMed Holdings ( (OBIO) ) has shared an announcement.
On February 19, 2025, Orchestra BioMed Holdings’ Compensation Committee approved several policies affecting its executive officers. A new policy was established for handling tax liabilities on restricted stock units (RSUs) for Section 16 Officers, allowing tax payments through share withholding instead of selling shares. Additionally, a new cash bonus plan was introduced, setting performance-based goals and stretch targets for 2025, with bonuses tied to achieving these objectives. The Committee also adopted a revised equity award policy and RSU vesting schedule for Vice Presidents and above, aimed at aligning executive incentives with long-term company success.
More about Orchestra BioMed Holdings
Orchestra BioMed Holdings, Inc. operates in the medical technology industry, focusing on the development of innovative therapeutic products. The company is engaged in advancing programs such as the BACKBEAT global pivotal study for blood pressure treatment and the Virtue Sirolimus AngioInfusion Balloon program for atherosclerotic artery disease.
YTD Price Performance: -11.15%
Average Trading Volume: 97,386
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $181.7M
See more data about OBIO stock on TipRanks’ Stock Analysis page.